Solvay
Market Cap
€8.0b
Last Updated
2020/10/19 20:57 UTC
Data Sources
Company Financials +
Executive Summary
Solvay SA operates as an advanced materials and specialty chemicals worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Fair value with moderate growth potential.
Similar Companies
Share Price & News
How has Solvay's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SOLB has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.2%
SOLB
-2.1%
BE Chemicals
-3.7%
BE Market
1 Year Return
-21.0%
SOLB
-12.2%
BE Chemicals
-22.9%
BE Market
Return vs Industry: SOLB underperformed the Belgian Chemicals industry which returned -10% over the past year.
Return vs Market: SOLB exceeded the Belgian Market which returned -22.6% over the past year.
Shareholder returns
| SOLB | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.2% | -2.1% | -3.7% |
| 30 Day | -3.6% | -7.4% | -2.7% |
| 90 Day | 6.3% | -7.0% | -4.0% |
| 1 Year | -18.3%-21.0% | -10.3%-12.2% | -21.7%-22.9% |
| 3 Year | -32.6%-38.1% | -19.4%-24.3% | -27.4%-31.8% |
| 5 Year | -6.4%-23.1% | 26.3%8.0% | -18.6%-26.9% |
Price Volatility Vs. Market
How volatile is Solvay's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Kind Of Investors Own Most Of Solvay SA (EBR:SOLB)?1 month ago | Simply Wall St
Calculating The Intrinsic Value Of Solvay SA (EBR:SOLB)1 month ago | Simply Wall St
Would Shareholders Who Purchased Solvay's(EBR:SOLB) Stock Three Years Be Happy With The Share price Today?Valuation
Is Solvay undervalued compared to its fair value and its price relative to the market?
48.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SOLB (€77.58) is trading below our estimate of fair value (€149.67)
Significantly Below Fair Value: SOLB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SOLB is unprofitable, so we can't compare its PE Ratio to the XE Chemicals industry average.
PE vs Market: SOLB is unprofitable, so we can't compare its PE Ratio to the Belgian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SOLB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SOLB is good value based on its PB Ratio (1.1x) compared to the BE Chemicals industry average (1.5x).
Next Steps
Future Growth
How is Solvay forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
69.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SOLB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: SOLB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SOLB's is expected to become profitable in the next 3 years.
Revenue vs Market: SOLB's revenue (3% per year) is forecast to grow slower than the Belgian market (7% per year).
High Growth Revenue: SOLB's revenue (3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SOLB's Return on Equity is forecast to be low in 3 years time (8.6%).
Next Steps
Past Performance
How has Solvay performed over the past 5 years?
-22.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SOLB is currently unprofitable.
Growing Profit Margin: SOLB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SOLB is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare SOLB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SOLB is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-10.9%).
Return on Equity
High ROE: SOLB has a negative Return on Equity (-23.97%), as it is currently unprofitable.
Next Steps
Financial Health
How is Solvay's financial position?
Financial Position Analysis
Short Term Liabilities: SOLB's short term assets (€4.5B) exceed its short term liabilities (€2.8B).
Long Term Liabilities: SOLB's short term assets (€4.5B) do not cover its long term liabilities (€7.1B).
Debt to Equity History and Analysis
Debt Level: SOLB's debt to equity ratio (45.4%) is considered high.
Reducing Debt: SOLB's debt to equity ratio has increased from 36.1% to 45.4% over the past 5 years.
Debt Coverage: SOLB's debt is well covered by operating cash flow (43.1%).
Interest Coverage: SOLB is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Solvay current dividend yield, its reliability and sustainability?
4.83%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SOLB's dividend (4.83%) is higher than the bottom 25% of dividend payers in the Belgian market (2.14%).
High Dividend: SOLB's dividend (4.83%) is low compared to the top 25% of dividend payers in the Belgian market (5.74%).
Stability and Growth of Payments
Stable Dividend: SOLB's dividend payments have been volatile in the past 10 years.
Growing Dividend: SOLB's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: SOLB is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: SOLB's dividends in 3 years are forecast to be well covered by earnings (49.3% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Ilham Kadri (51 yo)
1.58yrs
Tenure
€4,413,155
Compensation
Dr. Ilham Kadri has been Chief Executive Officer and Non independent Director at Solvay SA since March 1, 2019 and serves as its Chairman of Executive Committee. Dr. Kadri was an Executive Officer of Solva ...
CEO Compensation Analysis
Compensation vs Market: Ilham's total compensation ($USD5.20M) is above average for companies of similar size in the Belgian market ($USD2.14M).
Compensation vs Earnings: Insufficient data to compare Ilham's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Executive Committee | 1.58yrs | €4.41m | no data | |
| CFO & Member of the Executive Committee | 7yrs | €1.71m | no data | |
| Member of Executive Committee | 14.75yrs | €1.44m | no data | |
| President of Specialty Polymers & Member of the Executive Committee | 2.67yrs | €1.29m | no data | |
| President of the GBU Special Chem & Member of the Executive Committee | 2.67yrs | €1.34m | no data | |
| Chief People Officer & Member of Executive Committee | 1.08yrs | €547.02k | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Head of Legal & Compliance and Group General Counsel | 3.75yrs | no data | no data | |
| Group General Manager of Communications | 4.67yrs | no data | no data | |
| Group General Manager of Marketing & Sales | no data | no data | no data | |
| President of The Silica Global Business Unit | 6yrs | no data | no data |
3.8yrs
Average Tenure
54.5yo
Average Age
Experienced Management: SOLB's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Executive Committee | 1.58yrs | €4.41m | no data | |
| Independent Director | 6.42yrs | €89.50k | no data | |
| Chairman | 8.42yrs | €250.00k | no data | |
| Non Independent Non Executive Director | 14.58yrs | €95.00k | no data | |
| Independent Director | 6.75yrs | €90.00k | no data | |
| Non-Independent Director | 13.42yrs | no data | no data | |
| Independent Director | 5.42yrs | €111.00k | no data | |
| Independent Director | 7.25yrs | €37.94k | no data | |
| Independent Director | 11.75yrs | €99.00k | no data | |
| Independent Director | 10.75yrs | €109.00k | no data | |
| Independent Director | 7.25yrs | €92.00k | no data | |
| Independent Director | 3.42yrs | €95.00k | no data |
7.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: SOLB's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Solvay SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Solvay SA
- Ticker: SOLB
- Exchange: ENXTBR
- Founded: 1863
- Industry: Diversified Chemicals
- Sector: Materials
- Market Cap: €8.023b
- Shares outstanding: 103.41m
- Website: https://www.solvay.com
Number of Employees
Location
- Solvay SA
- Rue de Ransbeek, 310
- Brussels
- Brussels
- 1120
- Belgium
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SVYS.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| SOLB | ENXTBR (Euronext Brussels) | Yes | Ordinary Shares | BE | EUR | Jan 1992 |
| SOL | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| 0NZR | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| SOLBB | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| SOLB | WBAG (Wiener Boerse AG) | Yes | Ordinary Shares | AT | EUR | Jan 1992 |
| SOL | ETLX (Eurotlx) | Yes | Ordinary Shares | IT | EUR | Jan 1992 |
| SOLV.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Aug 2010 |
Biography
Solvay SA operates as an advanced materials and specialty chemicals worldwide. It operates through four segments: Advanced Materials, Advanced Formulations, Performance Chemicals, and Corporate & Business ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/19 20:57 |
| End of Day Share Price | 2020/10/19 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.